As previously reported, ccRCC features mutations mainly in VHL/HIF and PI3K/AKT/mTOR pathways [14], thus the currently approved therapeutical approaches involve VEGF or mTOR inhibitors (such as Tensirolimus or Everolimus), for advanced RCC. The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.